Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.

HOME
>
論文・技術情報
>
Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.

Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.

アブストラクト	PURPOSE: Valbenazine is commonly used to treat tardive dyskinesia, and we conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) to evaluate neurological safety signals associated with valbenazine. METHODS: Data was collected in FAERS from the second quarter of 2017 to the fourth quarter of 2023 for data cleaning. Neurological adverse event (AE) signals of valbenazine were mined by calculating reporting odds ratios (ROR), information component (IC) and empirical Bayesian geometric mean (EBGM). The serious and non-serious cases and signals were prioritized using a rating scale. RESULTS: The number of neurological AE reports where the primary suspect (PS) drug was 8981 for valbenazine. Significant AE signals were identified by the preferred term (PT) analysis for valbenazine, including somnolence (ROR 19.69), tremor (ROR 15.17), and tardive dyskinesia (ROR 236.91), among which 18 AEs were identified as new signals. Patient age (p < 0.009) and sex (p = 0.197) might be associated with an increased risk of neurological AE severity. Notably, the association between valbenazine and neurological disorders remained when stratified by sex, age, and reporter type. AE timing analysis was performed for the drug and four moderate clinical priority signals [i.e., somnolence, balance disorder, parkinsonism, and akathisia (priorities 7)], showing the same early failure type profiles. CONCLUSIONS: The increase in neurological safety signals is identified in the post-marketing research of valbenazine. Clinicians need to pay attention to not only common AEs but also be alert to new neurological AE signals when using valbenazine.
ジャーナル名	General hospital psychiatry
Pubmed追加日	2024/6/21
投稿者	Zhang, Yi; Jia, Xiaocan; Shi, Xuezhong; Chen, Yongyue; Xue, Mingyi; Shen, Guibin; Wen, Long; Qiao, Ying; Yang, Yongli
組織名	Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou;University, Zhengzhou 450001, Henan, China.;University, Zhengzhou 450001, Henan, China. Electronic address:;ylyang377@zzu.edu.cn.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/38901166/